LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Cancer Therapy Oncoinvent ASA specializes in receptor-independent alpha radiation therapy targeting residual micrometastases in the abdominal cavity, presenting a unique treatment modality with high potential for differentiation in the oncology market.

Strategic Merger The recent merger with BerGenBio enhances the company's R&D capabilities and broadens its pipeline, offering opportunities for collaborative development and cross-promotional strategies.

International Expansion With ongoing phase 2 studies in Norway and internationally, there is potential for partnerships to support clinical trial expansion, regulatory approvals, and market entry globally.

Funding and Growth With $23 million in funding and ongoing development, the company is positioned for growth in radiopharmaceuticals, providing opportunities for investment and sales of research tools or clinical support solutions.

Leadership and Visibility Key personnel appointments, including the hiring of a new CFO and CEO, indicate a strategic focus on operational growth and attracting investor interest, which could facilitate strategic collaborations or licensing agreements.

Similar companies to BerGenBio ASA - Merged with Oncoinvent ASA

BerGenBio ASA - Merged with Oncoinvent ASA Tech Stack

BerGenBio ASA - Merged with Oncoinvent ASA uses 8 technology products and services including WordPress, oEmbed, jQuery, and more. Explore BerGenBio ASA - Merged with Oncoinvent ASA's tech stack below.

  • WordPress
    Content Management System
  • oEmbed
    Dev Tools
  • jQuery
    Javascript Libraries
  • PHP
    Programming Languages
  • Bootstrap
    UI Frameworks
  • MediaElement.js
    Video Players
  • Nginx
    Web Servers
  • X-UA-Compatible
    Web Tools And Plugins

Media & News

BerGenBio ASA - Merged with Oncoinvent ASA's Email Address Formats

BerGenBio ASA - Merged with Oncoinvent ASA uses at least 2 format(s):
BerGenBio ASA - Merged with Oncoinvent ASA Email FormatsExamplePercentage
First.Last@bergenbio.comJohn.Doe@bergenbio.com
95%
Last@bergenbio.comDoe@bergenbio.com
3%
First_Last@bergenbio.comJohn_Doe@bergenbio.com
2%
Last@oncoinvent.comDoe@oncoinvent.com
48%
First.Last@oncoinvent.comJohn.Doe@oncoinvent.com
36%
First.Middle.Last@oncoinvent.comJohn.Michael.Doe@oncoinvent.com
15%
FirstL@oncoinvent.comJohnD@oncoinvent.com
1%

Frequently Asked Questions

Where is BerGenBio ASA - Merged with Oncoinvent ASA's headquarters located?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's main headquarters is located at 91 Jonas Lies Vei Bergen, Vestland 5009 Norway. The company has employees across 1 continents, including Europe.

What is BerGenBio ASA - Merged with Oncoinvent ASA's phone number?

Minus sign iconPlus sign icon You can contact BerGenBio ASA - Merged with Oncoinvent ASA's main corporate office by phone at
+47-55-54-3****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BerGenBio ASA - Merged with Oncoinvent ASA's official website and social media links?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's official website is oncoinvent.com and has social profiles on LinkedInCrunchbase.

What is BerGenBio ASA - Merged with Oncoinvent ASA's SIC code NAICS code?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BerGenBio ASA - Merged with Oncoinvent ASA have currently?

Minus sign iconPlus sign iconAs of April 2026, BerGenBio ASA - Merged with Oncoinvent ASA has approximately 6 employees across 1 continents, including Europe. Key team members include Chief People Officer: D. M.Full Time Senior Researcher, Vp Of Contract Services: T. S.Director Of Biomarkers And Research: D. M.. Explore BerGenBio ASA - Merged with Oncoinvent ASA's employee directory with LeadIQ.

What industry does BerGenBio ASA - Merged with Oncoinvent ASA belong to?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA operates in the Biotechnology Research industry.

What technology does BerGenBio ASA - Merged with Oncoinvent ASA use?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's tech stack includes WordPressoEmbedjQueryPHPBootstrapMediaElement.jsNginxX-UA-Compatible.

What is BerGenBio ASA - Merged with Oncoinvent ASA's email format?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's email format typically follows the pattern of First.Last@bergenbio.com. Find more BerGenBio ASA - Merged with Oncoinvent ASA email formats with LeadIQ.

How much funding has BerGenBio ASA - Merged with Oncoinvent ASA raised to date?

Minus sign iconPlus sign icon As of April 2026, BerGenBio ASA - Merged with Oncoinvent ASA has raised $23M in funding. The last funding round occurred on Nov 30, 2023 for $23M.

When was BerGenBio ASA - Merged with Oncoinvent ASA founded?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA was founded in 2008.

BerGenBio ASA - Merged with Oncoinvent ASA

Biotechnology ResearchVestland, Norway2-10 Employees

On 29 October 2025, BerGenBio ASA completed its merger with Oncoinvent ASA. The combined company now operates under the name Oncoinvent ASA.
Oncoinvent ASA is alone in developing cancer treatment using alpha radiation for patients with cancer in the abdominal cavity – a condition with very few treatment options and a high rate of recurrence. Preliminary studies show positive research findings. The company has begun recruitment for phase 2 studies, both in Norway and internationally.
For more information about the new company, please visit Oncoinvent ASA: https://www.linkedin.com/company/oncoinvent-as/

BerGenBio’s LinkedIn page will be maintained as a historical archive. 
BerGenBio was a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.

Section iconCompany Overview

Headquarters
91 Jonas Lies Vei Bergen, Vestland 5009 Norway
Phone number
+47-55-54-3****
Website
oncoinvent.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
2-10

Section iconMedia & News

Section iconFunding & Financials

  • $23M

    BerGenBio ASA - Merged with Oncoinvent ASA has raised a total of $23M of funding over 10 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $23M.

  • $1M

    BerGenBio ASA - Merged with Oncoinvent ASA's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $23M

    BerGenBio ASA - Merged with Oncoinvent ASA has raised a total of $23M of funding over 10 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $23M.

  • $1M

    BerGenBio ASA - Merged with Oncoinvent ASA's revenue is estimated to be in the range of $1M

Company Leadership

  • Stylized image of a person
    D. M.
    Chief People Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    T. S.
    Full Time Senior Researcher, Vp Of Contract Services
    Phone icon
    Mobile Phone
  • Stylized image of a person
    D. M.
    Director Of Biomarkers And Research
    Phone icon
    Mobile Phone
  • Stylized image of a person
    C. B. D.
    Finance Director
    Phone icon
    Mobile Phone

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.